Infusions, Parenteral

Publication Title: 
The Journal of Trauma

In this study, intravenous diazepam was a convenient, safe, and entirely adequate replacement of anesthesia for orthopaedia manipulations. It was administered in the hospital emergency room to both healthy and ill patients. A wide age range of patients was treated, and many very difficult reductions were accomplished. It is the author's firm opinion, however, that the physician using this technique should be capable of using emergency respiratory resuscitation equipment and that such equipment should be immediately available.

Author(s): 
Gunther, S. F.
Usnr, L. M.
Publication Title: 
Pediatrics

Hypnotherapy has many uses in pediatrics, and its value, not only as a adjunct but also as a primary therapy for certain conditions, justifies its inclusion in pediatric training programs. Suggestion and expectation have long been related to therapeutic outcomes in medicine, but not all physicians know how to apply them constructively and systematically in communication with patients. In pediatrics there is a tendency to overlook opportunities in which hypnosis might be the treatment of choice.

Author(s): 
Olness, K.
Gardner, G. G.
Publication Title: 
British Journal of Anaesthesia

Etomidate was injected i.v. within 10 or 60 s at various doses. After etomidate 0.3 mg kg-1 the plasma concentration was 1.6 micrograms ml-1 at 1 min after the end of injection. For about 7 min a good hypnotic effect (stages C0-D2) was observed on the e.e.g. recording. For surgical procedures, however, a combination with analgesic drugs appeared to be necessary. When the dose of etomidate was increased (0.1-0.4 mg kg-1) a linear increase in plasma concentration and slow e.e.g. activity was observed concomitantly.

Author(s): 
Doenicke, A.
Löffler, B.
Kugler, J.
Suttmann, H.
Grote, B.
Publication Title: 
Anaesthesia

A review of the hypnotic, anticonvulsant and brain protective action of etomidate in animals shows that when given as a single injection in different animal species recovery from hypnosis is quick and that the safety margin is large. In dogs a bolus or infusion produces high amplitude theta activity on the electroencephalogram (EEG). During infusion burst suppression is seen. After high doses, behaviour and EEG changes returned to normal within 3 hours. The wide spectrum of anticonvulsant activity suggests that etomidate may be useful in the treatment of status epilepticus.

Author(s): 
Wauquier, A.
Publication Title: 
Anesthesia and Analgesia

An etomidate infusion regimen for hypnosis as part of balanced, totally intravenous anesthesia was designed to maintain plasma etomidate concentrations above the awakening concentration of 300 ng/ml while avoiding dose-related side effects. The etomidate infusion regimen of 0.1 mg/kg/min for 3 min, 0.02 mg/kg/min for 27 min, and 0.01 mg/kg/min for the remainder of the anesthesia was used together with intravenous bolus doses of fentanyl, droperidol, and pancuronium. This was evaluated in 11 patients and the kinetics of etomidate were reexamined.

Author(s): 
Fragen, R. J.
Avram, M. J.
Henthorn, T. K.
Caldwell, N. J.
Publication Title: 
Journal of Pain and Symptom Management

Neuropathic cancer pain may be less responsive to opioids than other pain. Several studies suggest that N-methyl-D-aspartate (NMDA)-receptor antagonists could play a role in the treatment of neuropathic pain. Ketamine is an NMDA-receptor antagonist that is used as an anesthetic and has been suggested as a useful drug for neuropathic pain. Subanesthetic doses of ketamine can yield analgesia without hypnosis.

Author(s): 
Mercadante, S.
Lodi, F.
Sapio, M.
Calligara, M.
Serretta, R.
Publication Title: 
PloS One

BACKGROUND: Safe, cheap and effective adjunct therapies preventing the development of, or reducing the mortality from, severe malaria could have considerable and rapid public health impact. Oral activated charcoal (oAC) is a safe and well tolerated treatment for acute poisoning, more recently shown to have significant immunomodulatory effects in man.

Author(s): 
de Souza, J. Brian
Okomo, Uduak
Alexander, Neal D.
Aziz, Naveed
Owens, Benjamin M. J.
Kaur, Harparkash
Jasseh, Momodou
Muangnoicharoen, Sant
Sumariwalla, Percy F.
Warhurst, David C.
Ward, Stephen A.
Conway, David J.
Ulloa, Luis
Tracey, Kevin J.
Foxwell, Brian M. J.
Kaye, Paul M.
Walther, Michael
Publication Title: 
Bulletin of the World Health Organization

OBJECTIVE: To explore the cost-effectiveness of parenteral artesunate for the treatment of severe malaria in children and its potential impact on hospital budgets. METHODS: The costs of inpatient care of children with severe malaria were assessed in four of the 11 sites included in the African Quinine Artesunate Malaria Treatment trial, conducted with over 5400 children. The drugs, laboratory tests and intravenous fluids provided to 2300 patients from admission to discharge were recorded, as was the length of inpatient stay, to calculate the cost of inpatient care.

Author(s): 
Lubell, Yoel
Riewpaiboon, Arthorn
Dondorp, Arjen M.
von Seidlein, Lorenz
Mokuolu, Olugbenga A.
Nansumba, Margaret
Gesase, Samwel
Kent, Alison
Mtove, George
Olaosebikan, Rasaq
Ngum, Wirichada Pan
Fanello, Caterina I.
Hendriksen, Ilse
Day, Nicholas P. J.
White, Nicholas J.
Yeung, Shunmay
Publication Title: 
MMWR. Morbidity and mortality weekly report

Parenteral artesunate, a first-line treatment for severe malaria in several countries, is associated with increased survival and has a better safety profile compared with parenteral quinine or quinidine. However, parenteral artesunate has been associated with delayed hemolysis, leading to concerns about drug toxicity. Postartemisinin delayed hemolysis (PADH) can occur 1-3 weeks after initiation of treatment with artemisinin-based antimalarials such as artesunate and is characterized by a decline in hemoglobin levels amid hemolysis.

Author(s): 
Paczkowski, Magdalena M.
Landman, Keren L.
Arguin, Paul M.
Centers for Disease Control and Prevention (CDC)
Publication Title: 
Medizin, Gesellschaft, Und Geschichte: Jahrbuch Des Instituts Für Geschichte Der Medizin Der Robert Bosch Stiftung

Treatment of rheumatic and other diseases through immersion in an anthill is reported in German folk medicine. In the first half of the twentieth century, the physicians Eduard and Egon Krull (1842-1914 and 1879-1936, respectively) as well as Albrecht Reuter (1863-1937) recommended injections of diluted formic acid to treat tuberculosis, gout, arthritis, renal disorders and other complaints. Between 1930 and 1960, more than 15 different commercial preparations were marketed, and Egon Krull invented a drug series called "Myrmekan".

Author(s): 
Helmstädter, A.

Pages

Subscribe to RSS - Infusions, Parenteral